Market: NMS |
Currency: USD
Address: 680 West Nye Lane
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Show more
📈 BioVie Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-05-12
-
EPS Estimate:
-0.73
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for BioVie Inc.
| Date | Reported EPS |
|---|
| 2026-05-11 (estimated upcoming) | - |
| 2025-11-10 | -0.98 |
| 2025-08-15 | -11.05 |
| 2025-05-12 | -1.5 |
| 2025-02-11 | -4.6 |
| 2024-05-14 | -20 |
| 2024-02-13 | -22 |
| 2023-11-08 | -29 |
| 2023-08-16 | -23 |
| 2023-05-12 | -43 |
| 2023-02-10 | -50 |
| 2022-11-04 | -38 |
| 2022-09-27 | -33 |
| 2022-05-11 | -28 |
| 2022-02-08 | -22 |
| 2021-08-30 | -1018.77 |
| 2021-05-10 | -22 |
| 2021-01-29 | -22 |
📰 Related News & Research
No related articles found for "biovie inc".
